Canvas & Ratio
Choose your destination platform format
Layout Template
Choose a content structure for your slides
Preset Themes
Typography & Sizing
Brand Kit Customization
AGENCYConfigure brand assets for headers & footers
Outro Slide CTA
Customize your closing call-to-action slide
Background Pattern
Build Your Carousel
Drag and drop any post card below onto a slide, or use the quick buttons to insert content/images instantly!
๐จ BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's โ WITH ONE PILL. A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data. Phase 3 means that we are on the verge of FDA approval. It targets the ROOT CAUSE of both diseases simultaneously. Here's what you need to know ๐งต๐ #Alzheimers #Parkinsons
Tweet 2 Most people think Alzheimer's and Parkinson's are totally separate diseases. They're not. At autopsy, ~1 in 3 Alzheimer's patients have Lewy body (Parkinson's-type) protein in their brain. And ~50% of Lewy body dementia patients have full Alzheimer's pathology too. Same brain. Multiple diseases. Quietly overlapping. ๐ง That's called co-pathology โ and it's why targeting just one protein may never be enough. ๐ #Dementia #Neurodegeneration
There are FOUR driving neurodegeneration: ๐ด Amyloid-ฮฒ ๐ Tau ๐ก Alpha-Synuclein ๐ข TDP-43 Every approved drug targets just one of these. Buntanetap targets all four โ simultaneously. That's not an upgrade. That's a completely different philosophy. ๐ #Alzheimers #Buntanetap
How does it work? Buntanetap doesn't clean up protein AFTER it's already damaged your brain. It stops the proteins from being MADE in the first place. It binds to mRNA โ the blueprint โ before toxic proteins are assembled. Think of it as cutting the factory order, not cleaning up the mess. ๐ญ #Parkinsons #Neurodegeneration
The clinical trial results are IN. ๐ Phase 2/3 Study: โข 351 patients โข 54 sites across the US โข 3 doses tested โข 12 weeks Result: Statistically significant improvement in COGNITION in early Alzheimer's patients. The 30mg dose showed +3.3 points on the ADAS-Cog11 scale vs placebo. P < 0.001. ๐ฌ #Alzheimers #ClinicalTrials
But cognition is just one piece. The biomarker data is where it gets REALLY interesting. After treatment, researchers measured: ๐ Tau โ REDUCED ๐ TDP-43 โ REDUCED ๐ Neurofilament Light (NfL) โ REDUCED ๐ Neuroinflammation markers (IL-6, IFN-ฮณ) โ REDUCED This isn't just symptom relief. This is hitting the BIOLOGY. #Buntanetap #BrainHealth
Now for Parkinson's. Buntanetap also completed a Phase 3 PD trial. 523 patients. 6 months. Patients diagnosed 3+ years: โ Statistically significant motor improvements โ Cognitive decline HALTED overall โ Plasma tau REDUCED Alpha-synuclein is the main villain in Parkinson's. Buntanetap targets it too. This is rare. ๐ง #Parkinsons #ClinicalTrials
What about safety? This is where Big Pharma drugs often fail. Buntanetap: โ Well tolerated at ALL doses โ Safe in ApoE4 gene carriers (highest AD risk group) โ No major drug-related serious events โ Compatible with existing AD medications And it's a PILL. Not an IV infusion every two weeks. That alone is a massive advantage. ๐ #Alzheimers #Parkinsons
The FDA is paying attention. In October 2024: FDA cleared Annovis to proceed with Phase 3 trials in Alzheimer's. In February 2026: An independent safety board (DSMB) reviewed the ongoing Phase 3 and said: "No safety concerns. Continue as planned." This is a green light from independent watchdogs. ๐ฆ #Buntanetap #Alzheimers
The pivotal Phase 3 is happening RIGHT NOW. ๐ 760 patients ๐ 83 locations across the US ๐ Only biomarker-confirmed early AD (pTau217+) ๐ 18-month trial โ symptomatic + disease-modifying readouts โฑ๏ธ First results expected: Late 2026 / Early 2027 โฑ๏ธ Full disease-modification data: 2027โ2028 This is the make-or-break moment. ๐ฏ #Buntanetap #Alzheimers
The pivotal Phase 3 is happening RIGHT NOW. ๐ 760 patients ๐ 83 locations across the US ๐ Only biomarker-confirmed early AD (pTau217+) ๐ 18-month trial โ symptomatic + disease-modifying readouts โฑ๏ธ First results expected: Late 2026 / Early 2027 โฑ๏ธ Full disease-modification data: 2027โ2028 This is the make-or-break moment. ๐ฏ #Buntanetap #Alzheimers
Compare this to approved Alzheimer's drugs. Lecanemab & Donanemab (currently approved): โ IV infusion every 2 weeks โ Brain swelling risk (ARIA) โ Only targets amyloid โ ~$26,500/year Buntanetap (if approved): โ Once-daily pill โ Targets 4 proteins โ No IV โ Potentially far cheaper This is why researchers are excited. #Buntanetap #Neurodegeneration
Important caveats โ I won't hide them. โ ๏ธ The PD Phase 3 missed its primary endpoint overall (benefit was in subgroups only) โ ๏ธ The AD Phase 2/3 was only 12 weeks โ ๏ธ Disease modification is NOT YET proven โ Phase 3 is the real test โ ๏ธ No FDA approval yet The science is promising. But Phase 3 data (2026-2028) decides everything. This is not a guaranteed win. Stay skeptical AND curious. #Buntanetap #ClinicalTrials
So here's the bottom line: Buntanetap is: โ Oral, once daily โ Published in peer-reviewed journals (Nature, 2026) โ Phase 3 safety cleared โ Targeting 4 proteins no other approved drug touches simultaneously The pivotal results come in 2026โ2028. If it works, this changes everything. Follow for updates. Share if someone you love has AD or PD. ๐ง โค๏ธ [Full source list in reply ๐] #Alzheimers #Parkinsons #Buntanetap
Buntanetap is exciting because it targets multiple overlapping proteins that drive most cases. I wrote about this bigger shift ... Parkinsonโs as many different diseases here. Copathology needs to be addressed. <a target="_blank" href="https://neuroscope.substack.com/p/a-new-era-for-parkinsons-finally" color="blue">neuroscope.substack.com/p/a-new-era-foโฆ</a>